The detection and clinical significance of JAK2V617F mutations in myelodysplastic syndrome patients
10.3760/cma.j.issn.1008-6706.2016.04.024
- VernacularTitle:骨髓增生异常综合征患者外周血JAK2V617F 基因检测及临床意义
- Author:
Ting WANG
;
Linli PAN
;
Jie WU
;
Yanjun WANG
;
Lei ZHANG
;
Guangyao LI
- Publication Type:Journal Article
- Keywords:
Myelodysplastic syndrome;
Blood;
Gene,JAK2V617F
- From:
Chinese Journal of Primary Medicine and Pharmacy
2016;(4):573-576
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the pathogenesis of myelodysplastic syndrome (MDS)transformation, JAK2V617F mRNA expression levels were compared in peripheral blood of MDS-RA(refractory anemia,RA)and MDS-RAEB(RA with excess blasts,RAEB)patients.Methods JAK2V617F mRNA expression level was detected by fuorescent quantitative polymerase chain reaction(FQ-PCR),and this research reviewed 22 patients diagnosed with MDS,including outpatient and hospitalized patients.20 cases of normal control group were healthy ones.FQ-PCR method was applied to monitor JAK2V617F mRNA expression level in peripheral blood of MDS-RA and MDS-RAEB patients.Results The JAK2V617F gene was not expressed or expressed in healthy subjects,and the copy number was (3 851.96 ±470.46).The patients with MDS-RA(4 631.11 ±3 851.96)was significantly higher than that in healthy subjects(t =3.61,P <0.01);MDS-RAEB patients was (22 545.98 ±11 084.17),and was significantly higher than that in MDS-RA patients(t =4.87,P <0.01).Conclusion JAK2V617F signal transduction can play a role in the pathogenesis and transformation of MDS,and the detection of JAK2-V617F mRNA expression level is use-ful for monitoring progression,judging prognosis and gene regulation therapy of MDS.
